{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'addition, vinflunine is approved in Europe for treatment of mUC after failure of a prior', 'platinum-based regimen [Bellmunt et al, 2011].', 'KEYNOTE-045, a multicenter, randomized, active-controlled trial in patients with locally', 'advanced or mUC with disease progression on or after platinum-containing chemotherapy,', \"compared pembrolizumab to investigator's choice of paclitaxel, docetaxel, or vinflunine\", 'every 3 weeks [Bellmunt et al, 2017].', 'Although no labeled dosing guidelines for taxanes are available in this setting, this is the only', 'large randomized trial that has reported combined survival data for these agents, as such the', 'current phase 3 study of enfortumab VS chemotherapy will use the same choice of comparators', 'and their corresponding doses. Patients randomized to the chemotherapy arm in the', 'KEYNOTE-045 study were treated with paclitaxel (175 mg/m\u00b2), docetaxel (75 mg/m\u00b2) or', 'vinflunine (320 mg/m\u00b2), administered intravenously every 3 weeks. The overall proportion of', 'subjects receiving vinflunine in the control arm was capped at approximately 35% (KEYNOTE', 'protocol).', '2.3', 'Enppoints', '2.3.1', 'Primary Enppoints', 'os', '2.3.2', 'Secondary Endpoints', 'PFS1 by RECIST V1.1', 'ORR (CR + PR) by RECIST V1.1', 'DCR (CR + PR + SD) by RECIST V1.1', 'DOR by RECIST V1.1', 'Safety variables (e.g., AEs, laboratory tests, vital sign measurements, 12-lead ECG and', 'ECOG PS)', 'QOL and PRO parameters (QLQ-C30 and EQ-5D-5L)', '2.3.3', 'Exploratory Enppoints', 'Exploratory genomic and/or other biomarkers in tumor tissue and in peripheral blood', 'that may correlate with treatment outcome, including Nectin-4 expression', 'Plasma or serum concentrations of TAb, ADC and MMAE', 'Incidence of ATA to EV', 'PFS2', 'HRU', '14 Sep 2020', 'Astellas', 'Page 47 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '3', 'STUDY POPULATION', '3.1', 'Selection of Study Population', 'Patients with locally advanced or metastatic urothelial cancer previously treated with', 'platinum-based chemotherapy and an immune checkpoint inhibitor (CPI).', '3.2', 'Inclusion Criteria', 'Subject is eligible for the study if all of the following apply:', '1.', 'Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written', 'informed consent and privacy language as per national regulations (e.g., Health', 'Insurance Portability and Accountability Act [HIPAA] Authorization for US sites) must', 'be obtained from the subject prior to any study-related procedures (including withdrawal', 'of prohibited medication, if applicable).', '2. Subject is legally an adult according to local regulation at the time of signing informed', 'consent.', '3. Subject has histologically or cytologically confirmed urothelial carcinoma (i.e., cancer of', 'the bladder, renal pelvis, ureter, or urethra). Subjects with urothelial carcinoma', '(transitional cell) with squamous differentiation or mixed cell types are eligible.', '4.', 'Subject must have experienced radiographic progression or relapse during or after a CPI', '(anti-programmed cell death protein-1 [PD-1] or anti-programmed cell death-ligand 1', '[PD-L1]) for locally advanced or metastatic disease. Subjects who discontinued CPI', 'treatment due to toxicity are eligible provided that they have evidence of disease', 'progression following discontinuation. The CPI need not be the most recent therapy.', 'Subjects for whom the most recent therapy has been a non-CPI based regimen are', 'eligible if they have progressed/relapsed during or after their most recent therapy.', 'Locally advanced disease must not be amenable to resection with curative intent per the', 'treating physician.', '5. Subject must have received a platinum containing regimen (cisplatin or carboplatin) in', 'the metastatic/locally advanced, neoadjuvant or adjuvant setting. If platinum was', 'administered in the adjuvant/neoadjuvant setting subject must have progressed within', '12 months of completion.', '6.', 'Subject has radiologically documented metastatic or locally advanced disease at', 'baseline.', '7.', 'An archival tumor tissue sample should be available for submission to central laboratory', 'prior to study treatment. If an archival tumor tissue sample is not available, a fresh tissue', 'sample should be provided. If a fresh tissue sample cannot be provided due to safety', 'concerns, enrollment into the study must be discussed with the medical monitor.', '8.', 'Subject has ECOG PS of 0 or 1.', '14 Sep 2020', 'Astellas', 'Page 48 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}